Frederick J Raal

List of Publications by Citations

199 papers	16,634 citations	50 h-index	128 g-index
224 ext. papers	20,697 ext. citations	8.1 avg, IF	6.41 L-index

#	Paper	IF	Citations
199	Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. *European Heart Journal*, **2013**, 34, 3478-90a	9.5	1551
198	Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. *New England Journal of Medicine*, **2015**, 372, 1489-99	59.2	1347
197	Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. *European Heart Journal*, **2017**, 38, 2459-2472	9.5	1267
196	Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. *New England Journal of Medicine*, **2015**, 372, 1500-9	59.2	1081
195	Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. *European Heart Journal*, **2015**, 36, 1012-22	9.5	770
194	Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. *Lancet, The*, **2010**, 375, 998-1006	40	684
193	Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. *European Heart Journal*, **2014**, 35, 2146-57	9.5	614
192	Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. *Lancet, The*, **2015**, 385, 341-50	40	497
191	PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. *Lancet, The*, **2015**, 385, 331-40	40	493
190	Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. *European Heart Journal*, **2015**, 36, 2425-37	9.5	430
189	Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. *Circulation*, **2012**, 126, 2408-17	16.7	386
188	The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association. *Circulation*, **2015**, 132, 2167-92	16.7	377
187	The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. *Lancet Diabetes and Endocrinology,the*, **2014**, 2, 655-66	18.1	357
186	Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. *New England Journal of Medicine*, **2020**, 382, 1507-1519	59.2	302
185	Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. *European Heart Journal*, **2020**, 41, 2313-2330	9.5	301
184	Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. *Journal of the American College of Cardiology*, **2014**, 63, 1278-1288	15.1	266
183	Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. *International Journal of Cardiology*, **2014**, 171, 309-25	3.2	251

182	Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. *Circulation*, **2013**, 128, 2113-20	16.7	246
181	Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. *Circulation*, **2011**, 124, 2202-7	16.7	235
180	Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. *Atherosclerosis*, **2012**, 223, 262-8	3.1	233
179	Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. *Lancet Diabetes and Endocrinology,the*, **2016**, 4, 850-61	18.1	215
178	Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. *New England Journal of Medicine*, **2020**, 382, 1520-1530	59.2	197
177	Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial. *Circulation*, **2014**, 129, 234-43	16.7	180
176	Evinacumab for Homozygous Familial Hypercholesterolemia. *New England Journal of Medicine*, **2020**, 383, 711-720	59.2	166
175	Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. *European Heart Journal*, **2018**, 39, 2526-2539	9.5	156
174	Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study. *Lancet Diabetes and Endocrinology,the*, **2017**, 5, 280-290	18.1	148
173	PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role. *Journal of Lipid Research*, **2016**, 57, 1086-96	6.3	138
172	Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2015**, 35, 689-99	9.4	133
171	Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher. *Cardiovascular Drugs and Therapy*, **2016**, 30, 473-483	3.9	125
170	Familial hypercholesterolaemia: A global call to arms. *Atherosclerosis*, **2015**, 243, 257-9	3.1	123
169	Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data. *Lancet Diabetes and Endocrinology,the*, **2016**, 4, 403-10	18.1	110
168	Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. *European Heart Journal*, **2014**, 35, 2249-59	9.5	106
167	Lipoprotein(a) in homozygous familial hypercholesterolemia. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2000**, 20, 522-8	9.4	99
166	Effect of Alirocumab on Lipoprotein(a) Over 1.5 Years (from the Phase 3 ODYSSEY Program). *American Journal of Cardiology*, **2017**, 119, 40-46	3	98
165	Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study. *JAMA Cardiology*, **2017**, 2, 598-607	16.2	97

164	Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). *Atherosclerosis*, **2018**, 277, 234-255	3.1	93
163	Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapy. *Journal of the American Heart Association*, **2013**, 2, e000028	6	92
162	Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia. *Atherosclerosis*, **1997**, 135, 249-56	3.1	82
161	Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation. *Journal of Clinical Lipidology*, **2014**, 8, 148-72	4.9	79
160	Familial hypercholesterolemia treatments: Guidelines and new therapies. *Atherosclerosis*, **2018**, 277, 483-492	3.1	72
159	A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia. *Atherosclerosis*, **2008**, 197, 400-6	3.1	71
158	Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia. *Atherosclerosis*, **2000**, 150, 421-8	3.1	70
157	Cardiovascular risk factor burden in Africa and the Middle East: the Africa Middle East Cardiovascular Epidemiological (ACE) study. *PLoS ONE*, **2014**, 9, e102830	3.7	70
156	Reduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9. *Annual Review of Medicine*, **2014**, 65, 417-31	17.4	69
155	Long-Term Evolocumab in Patients With Familial Hypercholesterolemia. *Journal of the American College of Cardiology*, **2020**, 75, 565-574	15.1	65
154	Effect of moderate dietary protein restriction on the progression of overt diabetic nephropathy: a 6-mo prospective study. *American Journal of Clinical Nutrition*, **1994**, 60, 579-85	7	63
153	Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. *Atherosclerosis Supplements*, **2016**, 22, 1-32	1.7	60
152	Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia. *Journal of the American College of Cardiology*, **2019**, 74, 2132-2146	15.1	58
151	Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol. *European Heart Journal*, **2018**, 39, 1162-1168	9.5	54
150	Pathogenesis of non-insulin-dependent diabetes mellitus in the black population of southern Africa. *Lancet, The*, **1992**, 340, 460-2	40	52
149	Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2018**, 38, 592-598	9.4	49
148	Colesevelam hydrochloride: efficacy and safety in pediatric subjects with heterozygous familial hypercholesterolemia. *Journal of Pediatrics*, **2010**, 156, 231-6.e1-3	3.6	49
147	Nonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB Council. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2015**, 35, 2269-80	9.4	48

146	Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. *Lancet Diabetes and Endocrinology,the*, **2020**, 8, 50-67	18.1	48
145	A longitudinal study of stavudine-associated toxicities in a large cohort of South African HIV infected subjects. *BMC Infectious Diseases*, **2011**, 11, 244	4	47
144	Low-density lipoprotein cholesterol bulk is the pivotal determinant of atherosclerosis in familial hypercholesterolemia. *American Journal of Cardiology*, **1999**, 83, 1330-3	3	44
143	Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care. *Nature Reviews Cardiology*, **2020**, 17, 360-377	14.8	41
142	Recent origin and spread of a common Lithuanian mutation, G197del LDLR, causing familial hypercholesterolemia: positive selection is not always necessary to account for disease incidence among Ashkenazi Jews. *American Journal of Human Genetics*, **2001**, 68, 1172-88	11	40
141	Suboptimal Control of Lipid Levels: Results from 29 Countries Participating in the Centralized Pan-Regional Surveys on the Undertreatment of Hypercholesterolaemia (CEPHEUS). *Journal of Atherosclerosis and Thrombosis*, **2016**, 23, 567-87	4	38
140	Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia. *Atherosclerosis*, **2003**, 171, 273-9	3.1	37
139	Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. *European Journal of Preventive Cardiology*, **2015**, 22, 849-54	3.9	35
138	From lipodystrophy syndromes to diabetes mellitus. *Lancet, The*, **2001**, 357, 1379-81	40	35
137	Phenotype diversity among patients with homozygous familial hypercholesterolemia: A cohort study. *Atherosclerosis*, **2016**, 248, 238-44	3.1	35
136	The age of onset and sex distribution of insulin-dependent diabetes mellitus in Africans in South Africa. *Postgraduate Medical Journal*, **1993**, 69, 552-6	2	34
135	Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia. *Journal of Clinical Lipidology*, **2017**, 11, 1448-1457	4.9	32
134	Pathogenesis and management of the dyslipidemia of the metabolic syndrome. *Metabolic Syndrome and Related Disorders*, **2009**, 7, 83-8	2.6	32
133	New therapies for reducing low-density lipoprotein cholesterol. *Endocrinology and Metabolism Clinics of North America*, **2014**, 43, 1007-33	5.5	31
132	Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis. *Journal of the American College of Cardiology*, **2021**, 77, 1182-1193	15.1	31
131	Pediatric experience with mipomersen as adjunctive therapy for homozygous familial hypercholesterolemia. *Journal of Clinical Lipidology*, **2016**, 10, 860-869	4.9	30
130	Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia: The ORION-2 Pilot Study. *Circulation*, **2020**, 141, 1829-1831	16.7	29
129	Efficacy of Rosuvastatin in Children With Homozygous Familial Hypercholesterolemia and Association With Underlying Genetic Mutations. *Journal of the American College of Cardiology*, **2017**, 70, 1162-1170	15.1	28

128	Different lipid profiles according to ethnicity in the Heart of Soweto study cohort of de novo presentations of heart disease. *Cardiovascular Journal of Africa*, **2012**, 23, 389-95	0.7	28
127	Cell adhesion molecules - can they be used to predict coronary artery disease in patients with familial hypercholesterolaemia?. *Clinica Chimica Acta*, **2000**, 293, 105-13	6.2	26
126	Efficacy of vitamin E compared with either simvastatin or atorvastatin in preventing the progression of atherosclerosis in homozygous familial hypercholesterolemia. *American Journal of Cardiology*, **1999**, 84, 1344-6, A7	3	25
125	Susceptibility of low density lipoprotein to oxidation in familial hypercholesterolaemia. *Atherosclerosis*, **1995**, 115, 9-15	3.1	25
124	Targeting LDL: is lower better and is it safe?. *Best Practice and Research in Clinical Endocrinology and Metabolism*, **2014**, 28, 309-24	6.5	23
123	Characterization of six patients who are double heterozygotes for familial hypercholesterolemia and familial defective apo B-100. *Arteriosclerosis and Thrombosis: A Journal of Vascular Biology*, **1993**, 13, 1076-81		23
122	Lomitapide for homozygous familial hypercholesterolaemia. *Lancet, The*, **2013**, 381, 7-8	40	22
121	Leptin, adiponectin, and high-sensitivity C-reactive protein in relation to the metabolic syndrome in urban South African blacks with and without coronary artery disease. *Metabolic Syndrome and Related Disorders*, **2009**, 7, 243-8	2.6	22
120	Improved glucose tolerance after effective lipid-lowering therapy with bezafibrate in a patient with lipoatrophic diabetes mellitus: a putative role for Randle's cycle in its pathogenesis?. *Clinical Endocrinology*, **1997**, 46, 365-8	3.4	22
119	Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia. *Journal of Clinical Lipidology*, **2015**, 9, 201-9	4.9	21
118	Consistent LDL-C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies. *Clinical Cardiology*, **2018**, 41, 1328-1335	3.3	21
117	Double-Blind Comparison of the Efficacy and Tolerability of Simvastatin and Fluvastatin in Patients with Primary Hypercholesterolaemia. *Clinical Drug Investigation*, **1995**, 10, 127-38	3.2	21
116	Future Directions to Establish Lipoprotein(a) as a Treatment for Atherosclerotic Cardiovascular Disease. *Cardiovascular Drugs and Therapy*, **2016**, 30, 101-8	3.9	21
115	Statins and other lipid-lowering therapy and pregnancy outcomes in homozygous familial hypercholesterolaemia: A retrospective review of 39 pregnancies. *Atherosclerosis*, **2018**, 277, 502-507	3.1	21
114	Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2016**, 36, 1647-50	9.4	19
113	Lomitapide and Mipomersen-Inhibiting Microsomal Triglyceride Transfer Protein (MTP) and apoB100 Synthesis. *Current Atherosclerosis Reports*, **2019**, 21, 48	6	19
112	CpG hotspot mutations at the LDL receptor locus are a frequent cause of familial hypercholesterolaemia among South African Indians. *Clinical Genetics*, **1997**, 51, 394-8	4	18
111	Lipid-Lowering Drug Therapy for CVD Prevention: Looking into the Future. *Current Cardiology Reports*, **2015**, 17, 104	4.2	17

110	The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis. *European Journal of Preventive Cardiology*, **2017**, 24, 1843-1850	3.9	17
109	Screening for diabetic retinopathy in South Africa with 60 degrees retinal colour photography. *Journal of Internal Medicine*, **1996**, 239, 43-7	10.8	17
108	Glycaemic, blood pressure and cholesterol control in 25 629 diabetics. *Cardiovascular Journal of Africa*, **2015**, 26, 188-92	0.7	17
107	Demographic and Clinical Factors Associated with Development of Type 2 Diabetes: A Review of the Literature. *International Journal of General Medicine*, **2020**, 13, 121-129	2.3	16
106	Polygenic familial hypercholesterolaemia: does it matter?. *Lancet, The*, **2013**, 381, 1255-7	40	16
105	Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT study. *Journal of Clinical Lipidology* , **2018**, 12, 1199-1207	4.9	15
104	Statin therapy in a kindred with both apolipoprotein B and low density lipoprotein receptor gene defects. *Atherosclerosis*, **1997**, 129, 97-102	3.1	15
103	A double mutant LDL receptor allele in a cypriot family with heterozygous familial hypercholesterolemia. *Human Genetics*, **1997**, 100, 101-3	6.3	15
102	Fewer bone histomorphometric abnormalities with intermittent than with continuous slow-release sodium fluoride therapy. *Osteoporosis International*, **1997**, 7, 376-89	5.3	14
101	The relationship between the development and progression of microalbuminuria and arterial blood pressure in type 1 (insulin-dependent) diabetes mellitus. *Diabetes Research and Clinical Practice*, **1992**, 16, 221-7	7.4	14
100	CEPHEUS SA: a South African survey on the undertreatment of hypercholesterolaemia. *Cardiovascular Journal of Africa*, **2011**, 22, 234-40	0.7	14
99	Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). *Lancet, The*, **2021**, 398, 1713-1725	40	14
98	Cardiovascular risk factor burden in Africa and the Middle East across country income categories: a post hoc analysis of the cross-sectional Africa Middle East Cardiovascular Epidemiological (ACE) study. *Archives of Public Health*, **2018**, 76, 15	2.6	13
97	High-dose statin therapy does not induce insulin resistance in patients with familial hypercholesterolemia. *Metabolic Syndrome and Related Disorders*, **2012**, 10, 351-7	2.6	13
96	Postprandial lipaemia, metabolic syndrome and LDL particle size in urbanised South African blacks with and without coronary artery disease. *QJM - Monthly Journal of the Association of Physicians*, **2008**, 101, 111-9	2.7	13
95	A randomized clinical trial comparing metabolic parameters after 48 weeks of standard- and low-dose stavudine therapy and tenofovir disoproxil fumarate therapy in HIV-infected South African patients. *HIV Medicine*, **2014**, 15, 3-12	2.7	12
94	Prevalence of dyslipidaemia in statin-treated patients in South Africa: results of the DYSlipidaemia International Study (DYSIS). *Cardiovascular Journal of Africa*, **2013**, 24, 330-8	0.7	12
93	Diabetogenic effect of tacrolimus in South African patients undergoing kidney transplantation1. *Transplantation*, **2002**, 73, 587-90	1.8	12

92	Familial hypercholesterolaemia and COVID-19: A two-hit scenario for endothelial dysfunction amenable to treatment. *Atherosclerosis*, **2021**, 320, 53-60	3.1	12
91	Prevalence and pattern of dyslipidaemia in type 2 diabetes mellitus patients at a tertiary care hospital. *Journal of Endocrinology Metabolism and Diabetes of South Africa*, **2017**, 22, 31-35	0.5	11
90	The achievement of glycaemic, blood pressure and LDL cholesterol targets in patients with type 2 diabetes attending a South African tertiary hospital outpatient clinic. *Journal of Endocrinology Metabolism and Diabetes of South Africa*, **2015**, 20, 81-86	0.5	11
89	Atherosclerosis seems not to be associated with hyperinsulinaemia in patients with familial hypercholesterolaemia. *Journal of Internal Medicine*, **1999**, 246, 75-80	10.8	11
88	Population specific genetic heterogeneity of familial hypercholesterolemia in South Africa. *Current Opinion in Lipidology*, **2018**, 29, 72-79	4.4	10
87	Trial evaluating evolocumab, a pcsk9 antibody, in patients with homozygous fh (tesla): Results of the randomized, double-blind, placebo-controlled trial. *Atherosclerosis*, **2014**, 235, e12	3.1	10
86	Insulin receptor substrate-1 gene variants in lipoatrophic diabetes mellitus and non-insulin-dependent diabetes mellitus: a study of South African black and white subjects. *Human Genetics*, **1997**, 101, 118-9	6.3	10
85	Autosomal recessive hypercholesterolaemia: discrimination of ARH protein and LDLR function in the homozygous FH phenotype. *Clinica Chimica Acta*, **2007**, 378, 33-7	6.2	10
84	Lack of effect of high dose vitamin E on xanthoma regression in homozygous familial hypercholesterolaemia. *Atherosclerosis*, **1994**, 107, 213-9	3.1	10
83	Inhibition of angiopoietin-like 3 for the management of severe hypercholesterolemia. *Current Opinion in Lipidology*, **2021**, 32, 213-218	4.4	10
82	Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia. *Cardiovascular Drugs and Therapy*, **2019**, 33, 69-76	3.9	9
81	Microalbuminuria is not associated with cardiovascular disease in patients with homozygous familial hypercholesterolaemia. *Atherosclerosis*, **1995**, 113, 289-92	3.1	9
80	The implementation of guidelines in a South African population with type 2 diabetes. *Journal of Endocrinology Metabolism and Diabetes of South Africa*, **2013**, 18, 154-158	0.5	8
79	Treatment Gaps Found in the Management of Type 2 Diabetes at a Community Health Centre in Johannesburg, South Africa. *Journal of Diabetes Research*, **2017**, 2017, 9536025	3.9	7
78	The early effects of stavudine compared with tenofovir on adipocyte gene expression, mitochondrial DNA copy number and metabolic parameters in South African HIV-infected patients: a randomized trial. *HIV Medicine*, **2013**, 14, 217-25	2.7	7
77	Adiponectin and atherosclerosis risk factors in African hemodialysis patients: a population at low risk for atherosclerotic cardiovascular disease. *Hemodialysis International*, **2012**, 16, 59-68	1.7	7
76	Mutation analysis in familial hypercholesterolemia patients of different ancestries: identification of three novel LDLR gene mutations. *Molecular and Cellular Probes*, **1998**, 12, 149-52	3.3	7
75	Comparison between surrogate indices of insulin sensitivity and resistance, and the hyperinsulinaemic euglycaemic glucose clamp in urban South African blacks with and without coronary artery disease. *Diabetes and Vascular Disease Research*, **2010**, 7, 151-7	3.3	6

74	The prevalence and incidence of and risk factors for, micro-albuminuria among urban Africans with type 1 diabetes in South Africa: An inter-ethnic study. *International Journal of Diabetes Mellitus*, **2010**, 2, 148-153		6
73	Low density lipoproteins and atherosclerosis-quantity or quality?. *Redox Report*, **1995**, 1, 171-6	5.9	6
72	Familial hypercholesterolemia: potential diagnostic value of mutation screening in a pediatric population of South Africa. *Clinical Genetics*, **1998**, 54, 74-8	4	5
71	Insulin-receptor activity in nondiabetic and diabetic urbanized South African black women. *Diabetes Care*, **1992**, 15, 277-81	14.6	5
70	Management of low-density lipoprotein cholesterol levels in South Africa: the International ChoLesterol management Practice Study (ICLPS). *Cardiovascular Journal of Africa*, **2019**, 30, 15-23	0.7	5
69	A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia. *Atherosclerosis*, **2021**, 325, 46-56	3.1	5
68	Multi-ethnic differences in HbA, blood pressure, and low-density-lipid cholesterol control among South Africans living with type 2 diabetes, after a 4-year follow-up. *International Journal of General Medicine*, **2016**, 9, 419-426	2.3	5
67	Never too old to benefit from lipid-lowering treatment. *Lancet, The*, **2020**, 396, 1608-1609	40	4
66	Analysis of mutations causing familial hypercholesterolaemia in black South African patients of different ancestr. *South African Medical Journal*, **2017**, 107, 145-148	1.5	4
65	Anacetrapib in familial hypercholesterolaemia: pros and cons. *Lancet, The*, **2015**, 385, 2124-6	40	4
64	South African Dyslipidaemia Guideline Consensus Statement:. *Journal of Endocrinology Metabolism and Diabetes of South Africa*, **2012**, 17, 155-165	0.5	4
63	The metabolic syndrome using the National Cholesterol Education Program and International Diabetes Federation definitions among urbanised black South Africans with established coronary artery disease. *Journal of Endocrinology Metabolism and Diabetes of South Africa*, **2007**, 12, 6-12	0.5	4
62	Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study.. *Lancet, The*, **2022**,	40	4
61	Long-term treatment with evolocumab homozygous familial hypercholesterolemia patients: Results from the trial assessing long-term use of PCSK9 inhibition in subjects with genetic LDL disorders (Taussig). *Atherosclerosis*, **2016**, 252, e44	3.1	4
60	Growth curve modelling to determine distinct BMI trajectory groups in HIV-positive adults on antiretroviral therapy in South Africa. *Aids*, **2019**, 33, 2049-2059	3.5	4
59	Patients with familial hypercholesterolemia and COVID-19: Efficient and ongoing cholesterol lowering is paramount for the prevention of acute myocardial infarction. *American Journal of Preventive Cardiology*, **2021**, 7, 100224	1.9	4
58	Genetic associations between serum low LDL-cholesterol levels and variants in LDLR, APOB, PCSK9 and LDLRAP1 in African populations. *PLoS ONE*, **2020**, 15, e0229098	3.7	3
57	Hypercholesterolemia in children and young adults current management. *Journal of Endocrinology Metabolism and Diabetes of South Africa*, **2009**, 14, 9-12	0.5	3

56	Case Studies: Unusual phaeochromocytomas in African families: the importance of genetic testing. *Journal of Endocrinology Metabolism and Diabetes of South Africa*, **2010**, 15, 92-94	0.5	3
55	Plasma fatty acid levels in South African interethnic male high school pupils at different ultimate risks of coronary heart disease. *Clinica Chimica Acta*, **1997**, 258, 31-46	6.2	3
54	Two novel and two known low-density lipoprotein receptor gene mutations in German patients with familial hypercholesterolemia. *Human Mutation*, **1998**, Suppl 1, S232-3	4.7	3
53	Quantity versus quality of LDL cholesterol in patients with familial hypercholesterolemia--which is more important?. *Clinica Chimica Acta*, **2001**, 314, 167-73	6.2	3
52	Insulin resistance or insulin deficiency as precursor of non-insulin-dependent diabetes mellitus. *Lancet, The*, **1994**, 344, 1705	40	3
51	Relationship between plasma insulin and blood pressure in South African black women in Johannesburg. *Diabetes Care*, **1992**, 15, 556-8	14.6	3
50	PCSK9 Inhibitors: From Nature's Lessons to Clinical Utility. *Endocrine, Metabolic and Immune Disorders - Drug Targets*, **2020**, 20, 840-854	2.2	3
49	The Effects of Mipomersen on Inhibiting Hepatic VLDL Apolipoprotein B100 Synthesis and Propensity for Hepatic Steatosis. *Clinical Chemistry*, **2016**, 62, 1052-3	5.5	3
48	Quality of care delivered to type 2 diabetes mellitus patients in public and private sector facilities in Johannesburg, South Africa. *International Journal of General Medicine*, **2018**, 11, 383-390	2.3	3
47	LONG-TERM EVOLOCUMAB USE IN SUBJECTS WITH HOMOZYGOUS AND SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: PRIMARY RESULTS OF THE TAUSSIG TRIAL. *Journal of the American College of Cardiology*, **2019**, 73, 1715	15.1	2
46	Increases in statin eligibility to reduce cardiovascular risk according to the 2013 ACC/AHA cholesterol guidelines in the Africa Middle East region: a sub-analysis of the Africa Middle East Cardiovascular Epidemiological (ACE) study. *BMC Cardiovascular Disorders*, **2019**, 19, 61	2.3	2
45	Retrospective analysis of cohort database: Phenotypic variability in a large dataset of patients confirmed to have homozygous familial hypercholesterolemia. *Data in Brief*, **2016**, 7, 1458-62	1.2	2
44	What matters most in pediatric familial hypercholesterolemia, genotype or phenotype?. *Journal of Lipid Research*, **2014**, 55, 793-5	6.3	2
43	Effects of Long-Term, Monthly Administration of the PCSK9 Inhibitor Evolocumab in Patients with Dysglycemia or Metabolic Syndrome. *Canadian Journal of Diabetes*, **2014**, 38, S18	2.1	2
42	Lower levels of high-density lipoprotein cholesterol in urban Africans presenting with communicable versus non-communicable forms of heart disease: the Heart of Soweto Hospital registry study. *BMJ Open*, **2014**, 4, e005069	3	2
41	The potential use of monoclonal antibodies and other novel agents as drugs to lower LDL cholesterol. *Clinical Lipidology*, **2013**, 8, 243-256		2
40	Circulating endothelium-related adhesion molecules in black South African patients with Graves disease. *Endocrine*, **2000**, 12, 21-3		2
39	Transcriptomic therapy for dyslipidemias utilizing nucleic acids targeted at ANGPTL3. *Future Cardiology*, **2021**,	1.3	2

38	Management of familial hypercholesterolemia in pregnancy. *Current Opinion in Lipidology*, **2021**, 32, 370-377	4.4	2
37	Pooled safety and efficacy of inclisiran in patients with statin intolerance (ORION-10 and ORION-11). *European Heart Journal*, **2020**, 41,	9.5	2
36	Why continued lipoprotein apheresis is vital for homozygous familial hypercholesterolemia patients with COVID-19. *Journal of Clinical Lipidology*, **2021**, 15, 379-380	4.9	2
35	DETECTION OF FAMILIAL HYPERCHOLESTEROLEMIA IN SOUTH AFRICA VIA CASCADE SCREENING: THE WITS FIND-FH PROGRAM. *Journal of the American College of Cardiology*, **2018**, 71, A1768	15.1	2
34	Clinical, demographic and genetic characteristics of homozygous familial hypercholesterolemia patients worldwide: Interim results from the hofh international clinical collaborators (HICC) registry. *Atherosclerosis*, **2018**, 275, e80	3.1	2
33	Familial hypercholesterolemia and COVID-19: A menacing but treatable vasculopathic condition. *Atherosclerosis Plus*, **2021**, 43, 3-6		2
32	An unusual presentation of insulinoma and the serious consequences of delayed diagnosis. *Journal of Endocrinology Metabolism and Diabetes of South Africa*, **2020**, 25, 28-30	0.5	1
31	Pattern of dyslipidaemia in relation to statin use in patients with type 2 diabetes mellitus attending a tertiary care hospital. *Journal of Endocrinology Metabolism and Diabetes of South Africa*, **2020**, 25, 6-11	0.5	1
30	Treatment effect of alirocumab according to age group, smoking status, and hypertension: Pooled analysis from 10 randomized ODYSSEY studies. *Journal of Clinical Lipidology*, **2019**, 13, 735-743	4.9	1
29	More aggressive lipid lowering in people with diabetes?. *Lancet Diabetes and Endocrinology,the*, **2019**, 7, 587-589	18.1	1
28	South African Dyslipidaemia Guideline Consensus Statement. *South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care*, **2013**, 55, 9-18	0.6	1
27	Postprandial hyperglycemia in urban South African blacks with and without coronary artery disease. *Metabolic Syndrome and Related Disorders*, **2009**, 7, 23-9	2.6	1
26	The role of increased gastrointestinal alcohol production in patients with the metabolic syndrome: Implications for the pathogenesis of non-alcoholic fatty liver disease. *Journal of Endocrinology Metabolism and Diabetes of South Africa*, **2008**, 13, 48-56	0.5	1
25	Basal endocrine status in African dietary iron overload. *Endocrine*, **2003**, 21, 241-4		1
24	LIPID AND LIPOPROTEIN LEVELS IN HIV-INFECTED ADULTS WITH SEPSIS COMPARED TO HEALTHY HIV- INFECTED CONTROLS. *African Journal of Infectious Diseases*, **2020**, 14, 1-9	0.5	1
23	Long-term safety and efficacy of alirocumab in South African patients with heterozygous familial hypercholesterolaemia: the ODYSSEY Open-Label Extension study. *Cardiovascular Journal of Africa*, **2019**, 30, 279-284	0.7	1
22	Novel therapies for familial hypercholesterolemia. *Current Opinion in Endocrinology, Diabetes and Obesity*, **2021**, 28, 188-195	4	1
21	Cascade Screening for Familial Hypercholesterolemia in South Africa: The Wits FIND-FH Program. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2020**, 40, 2747-2755	9.4	1

20	Hospitalized Children With Familial Hypercholesterolemia and COVID-19: A Case for Preventive Anticoagulation. *Frontiers in Cardiovascular Medicine*, **2021**, 8, 657719	5.4	1
19	Poor cardiovascular health is associated with subclinical atherosclerosis in apparently healthy sub-Saharan African populations: an H3Africa AWI-Gen study. *BMC Medicine*, **2021**, 19, 30	11.4	1
18	Hyperlipidemic myeloma, a rare form of acquired dysbetalipoproteinemia, in an HIV seropositive African female. *Clinica Chimica Acta*, **2021**, 520, 71-75	6.2	1
17	Cryptogenic Cushing Syndrome Due to a White Lie. *Clinical Chemistry*, **2020**, 66, 658-663	5.5	0
16	Homozygous familial hypercholesterolemia and its treatment by inclisiran. *Expert Opinion on Orphan Drugs*, **2020**, 8, 197-208	1.1	0
15	Fibroblast growth factor-23 in patients with homozygous familial hypercholesterolemia. *Journal of Clinical Lipidology*, **2018**, 12, 767-772	4.9	0
14	Prevention of Cardiovascular Burden in COVID-19 Patients Suffering from Familial Hypercholesterolemia: A Global Challenge. *Cardiology and Therapy*, **2021**, 11, 1	2.8	0
13	Acute Suppurative Thyroiditis Secondary to Infection.. *European Journal of Case Reports in Internal Medicine*, **2021**, 8, 003009	1.2	0
12	An unusual case of hypercholesterolaemia with liver dysfunction. *Journal of Endocrinology Metabolism and Diabetes of South Africa*, **2020**, 25, 31-35	0.5	
11	Pituitary apoplexy masquerading as meningitis. *Journal of Endocrinology Metabolism and Diabetes of South Africa*, **2016**, 21, 3-4	0.5	
10	The half-yellow man. *Journal of Endocrinology Metabolism and Diabetes of South Africa*, **2015**, 20, 140-141	0.5	
9	Statin benefits in people with cardiovascular risk factors only. *Journal of Endocrinology Metabolism and Diabetes of South Africa*, **2009**, 14, 146-146	0.5	
8	New-onset diabetes mellitus after renal transplantation. *Journal of Endocrinology Metabolism and Diabetes of South Africa*, **2008**, 13, 98-104	0.5	
7	Hypercholesterolaemia in children and young adults□urrent management. *South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care*, **2008**, 50, 7-10	0.6	
6	Dyslipidaemia in diabetes□n approach to therapeutic intervention. *South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care*, **2006**, 48, 42-47	0.6	
5	Opportunities for preventing further endothelial dysfunction in pregnant COVID-19 patients with familial hypercholesterolemia.. *Journal of Clinical Lipidology*, **2022**,	4.9	
4	Hyperpigmentation from Addison□s Disease. *New England Journal of Medicine*, **2021**, 384, 1752	59.2	
3	A pain in the neck. *BMJ, The*, **2019**, 367, l6008	5.9	

2	Agranulocytosis as a Side-Effect of Carbimazole. *Wits Journal of Clinical Medicine*, **2022**, 4, 61-63	0.5
1	Statins: are they appropriate for all patients?. *The Lancet Global Health*, **2022**, 10, e305-e306	13.6